ENDOPLY System in Humans: a Pilot Study

NCT ID: NCT06292728

Last Updated: 2025-02-25

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-09
• Study Completion Date: 2025-12-31

Brief Summary

Prospective, non-randomized study aimed at defining the initial pattern of gastric plication with the ENDOPLY System, and assess feasibility, ergonomics and safety of the device Prospective, single-centre, open label, consecutive enrolment

Detailed Description

This is a clinical trial of the ENDOPLY System medical device. Clinical data of 10 obese patients (obesity grade I and II) will be analysed. The ENDOPLY System medical device will be used to perform endoscopic internal plication of the stomach. This clinical trial may lead to an extension of the portfolio of medical devices used to perform endoscopic internal gastric plication.

Participation in this clinical trial may help individual trial subjects follow a strict diet that may lead to weight loss. Weight reduction may improve the overall health, quality of life and life expectancy of the trial subjects, but this cannot be guaranteed.

In this clinical trial, the gastric volume reduction procedure using the ENDOPLY System is performed under general anaesthesia. Under general anaesthesia, the ENDOPLY Platform is inserted through the mouth into the oesophagus and upper stomach, after a preliminary endoscopy for standard evaluation. The 5 mm endoscope allows to choose the initial site of the plications, most likely and according to similar techniques at the incisura (junction between the fundus and the antrum). 10 to 15 ligatures will be placed in the upward directions, thereby narrowing the gastric lumen. The investigator will determine during the procedure if the experimented device suits the regular pattern of plication that have been tested over the years in the literature concerning gastric plication.

Gastric volume reduction procedures using the ENDOPLY System may be associated with risks. There is a possibility of rare or unknown side effects. Risks associated with the investigational device (ENDOPLY System) - expected gastric fold fibrosis without adverse local inflammatory reaction. Patients will be administered standard medications as part of the "Standard of Care" endoscopic gastric examination under general anaesthesia.

Subjects participating in this clinical trial will attend regular follow-up appointments at 1, 3, 6, and 12 months after endoscopic internal plication of the stomach as specified in the study protocol.

ENDOPLY System technical information:

The ENDOPLY medical device does not contain as an integral part a medicinal substance or a derivative of human blood or plasma. The ENDOPLY medical device is not manufactured using tissues of animal origin, in order to minimise the risk of transmission of Transmissible Spongiform Encephalopathy to human. The ENDOPLY medical device complies with the essential the requirements laid down for medical devices in conformity assessment under other legislation governing technical requirements for products, with the exception of those aspects which are the subject of clinical trial. Precautions have been taken to protect health and safety with regard to those aspects of the user and the patients. The ENDOPLY medical device does not have a European Union Certificate for now.

Preliminary tests have included preliminary design-freeze and proof of concept, in-vivo studies at the Veterinary school of Lyon in 3 pigs, with an autopsy at three months and pathology samples analysis that have shown the expected fibrosis of gastric folds without adverse local inflammatory reaction.

ENDOPLY System is made by the company ENDOPLY (Lyon, France). The ENDOPLY System has the same goal as the other devices achieving an internal gastric plication, means APOLLO System (means Apollo Endoscopic surgery), ENDOMINA (means comprised of a triangulation platform and an instrument for tissue piercing and approximation) and Medical's Incisionless Operating Platform-primary obesity surgery endoluminal procedure). The ENDOPLY System aims at narrowing the gastric lumen by the mean of separated folds of the internal gastric wall.

The ENDOPLY Platform - Like its competitors, it is an endoscopic tissue approximation device, with the following parts:

• Handle: it is comprised of two parts that are when the jaws need to be closed.
• The system is made of several channels are put together and assembled within a shaft:
• A 5.6 mm channel for the endoscope (paediatric naso-fibroscope), for the time being.
• A 3 mm channel for the endoscopic grasper.
• A 5 mm channel for the ligature holder.
• The ligature: it consists in a 7 cm plastic barbed special tie made in Polyetheretherketone (PEEK), with a self-adjusting mechanism (locker) and fits into a ligature-holder.
• As a secondary step, a box containing reloads will be installed, thus avoiding frequent in-and-out manipulations. The reload will be also automatized, but those upgrades will not be available for the trial.
• The extremity of the platform, including delivery catheters outside of the inner perimeter (that is out of the patient's mouth), has been designed to be ergonomic.

Conditions

Obesity

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DEVICE_FEASIBILITY
• Blinding Strategy: NONE

Study Groups

Treatment

Group Type: EXPERIMENTAL

ENDOPLY System

Intervention Type: DEVICE

One endoscopic procedure where the ENDOPLY System is used for endoscopic gastric plication.

Interventions

ENDOPLY System

One endoscopic procedure where the ENDOPLY System is used for endoscopic gastric plication.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. BMI 30-40, i.e. class I and II obese patients

2. Age above 18 and below 60 years

3. Having failed multiples diet attempts

Exclusion Criteria

1. Achalasia and other oesophageal motility disorders

2. Severe esophagitis

3. Gastroduodenal ulcer

4. Heart disease and hypertension without treatment

5. Pulmonary, renal or hepatic failure, cancer

6. Pregnancy ongoing, scheduled or in the past months

7. Previous bariatric surgery or endoscopic bariatric technique

8. Participation to another study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Just 4 Device s.r.o.

UNKNOWN

Sponsor Role: collaborator

ENDOPLY

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jerome Dargent, MD

Role: STUDY_DIRECTOR

CEO, chief executive

Locations

Fakultní nemocnice u sv. Anny v Brně, Gastroenterologické a hepatologické oddělení

Brno, , Czechia

Site Status: RECRUITING

Countries

Czechia

Central Contacts

Jerome Dargent, MD

Role: CONTACT

jerome.dargent@polyclinique-rillieux.fr

0033681472286

Jitka Macháčková, M.Sc.

Role: CONTACT

machackova@endohope.cz

Facility Contacts

Jan Martínek, prof,MD,PhD

Role: primary

jan.martinek@fnusa.cz

Evžen Machytka, MD,PhD

Role: backup

evmac@seznam.cz

Other Identifiers

ENDOPLY1

Identifier Type: -

Identifier Source: org_study_id